Reading STE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STE free→Reading STE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STE free→QuarterlyIQ Insights · STE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Director — Richard C. Breeden: Mr. Breeden retired from the Board, and Pierre Boulud was appointed as a new Director.
senior financial advisor — Michael J. Tokich: Mr. Tokich's employment was extended on a part-time basis with changes to his compensation and benefits.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Director — Dr. Richard Steeves: Dr. Richard Steeves is retiring from the Board of Directors after 10 years of service.
Other Events. On March 3, 2025, Isomedix Operations, Inc. (“Isomedix”), a subsidiary of STERIS plc (“STERIS” or the “Company”), entered into binding confidential term sheets with plaintiffs’ counsel (the “Term Sheets”), as well as settlement agreements with several plaintiffs currently scheduled for trial. The Term Sheets and the settlement agreements are expected to resolve substantially all of the claims for personal injury related to ethylene oxide (“EO”) that are currently pending in the…
Regulation FD Disclosure. Reference is made to the Current Report on Form 8-K dated April 11, 2024 of STERIS plc (“STERIS” or the “Company”) pursuant to which STERIS reported that STERIS Corporation, a wholly owned subsidiary of the Company, and certain affiliates, entered into an Equity Purchase Agreement to sell STERIS’s Dental business segment to HuFriedy Group Holding LLC, an affiliate of Peak Rock Capital LLC, for $787.5 million, subject to customary adjustments, and up to an additional…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 27, 2023, Dr. Esther Alegria was appointed to serve on the Compliance and Technology Committee and the Nominating and Governance Committee of the Board. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly author…
Regulation FD Disclosure Reference is made to the Current Report on Form 8-K dated December 20, 2021 of STERIS plc (“STERIS” or the “Company”) pursuant to which STERIS reported that subsidiaries of STERIS had entered into an Asset Purchase Agreement to sell STERIS’s Renal Care business to certain subsidiaries of Evoqua Water Technologies Corp., for cash consideration of approximately $196 million, subject to certain potential adjustments, including a customary working capital adjustment. The…
Regulation FD Disclosure On December 20, 2021, subsidiaries of STERIS plc (“STERIS” or “the Company”) entered into an Asset Purchase Agreement to sell STERIS’s Renal Care business to certain subsidiaries of Evoqua Water Technologies Corp., for cash consideration of approximately $196 million, subject to certain potential adjustments, including a customary working capital adjustment. The transaction is subject to customary closing conditions, including regulatory review, and is anticipated to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 29, 2021, Paul E. Martin was appointed to serve on the Compliance and Technology Committee and the Compensation and Organization Development Committee of the Board. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto d…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.